ReviewTheranostics2026
Illumination of Targeting Nanotherapeutics with Precision Eyes: From Optical to Radio-nanotheranostics.
Review in Theranostics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer continues to rank among the deadliest diseases globally, claiming numerous lives due to its high mortality rates. Chemotherapy, a primary form of cancer treatment, offers significant benefits but is hampered by drawbacks that compromise patients' quality of life. Consequently, developing minimally invasive treatment alternatives remains a formidable challenge. Among these, nanomaterial-based, light-activated phototherapies-including photodynamic therapy, photothermal therapy, and radiotherapy-emerge as promising options, providing precise spatial and temporal control with reduced invasiveness. Advances in nanoscience and engineering have led to the creation of nanoparticles (NPs) that integrate therapeutic and diagnostic capabilities, known as theranostics, which enhance the effectiveness of clinical cancer management. This review summarizes recent advancements in nanotheranostics, spanning optical to radio-based approaches. We discuss the roles of various nanomaterials, such as upconversion NPs, gold NPs, nano-scintillators, and mesoporous silica NPs, among others, highlighting their dual diagnostic and therapeutic functionalities. Furthermore, NP-mediated induction of programmed cell death mechanisms-ferroptosis, pyroptosis, and cuproptosis-underscoring their significance in targeted cancer therapies and immune modulation were also explored. Additionally, we discuss how NPs can activate the stimulator of interferon genes pathway, amplify antitumor immunity and offer new avenues for improving cancer treatment outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.